Literature DB >> 32367441

Characterization of the N6-etheno-bridge method to assess extracellular metabolism of adenine nucleotides: detection of a possible role for purine nucleoside phosphorylase in adenosine metabolism.

Edwin K Jackson1, Delbert G Gillespie2, Dongmei Cheng2, Zaichuan Mi2, Elizabeth V Menshikova2.   

Abstract

The goal of this study was to determine the validity of using N6-etheno-bridged adenine nucleotides to evaluate ecto-nucleotidase activity. We observed that the metabolism of N6-etheno-ATP versus ATP was quantitatively similar when incubated with recombinant CD39, ENTPD2, ENTPD3, or ENPP-1, and the quantitative metabolism of N6-etheno-AMP versus AMP was similar when incubated with recombinant CD73. This suggests that ecto-nucleotidases process N6-etheno-bridged adenine nucleotides similarly to endogenous adenine nucleotides. Four cell types rapidly (t1/2, 0.21 to 0.66 h) metabolized N6-etheno-ATP. Applied N6-etheno-ATP was recovered in the medium as N6-etheno-ADP, N6-etheno-AMP, N6-etheno-adenosine, and surprisingly N6-etheno-adenine; intracellular N6-etheno compounds were undetectable. This suggests minimal cellular uptake, intracellular metabolism, or deamination of these compounds. N6-etheno-ATP, N6-etheno-ADP, N6-etheno-AMP, N6-etheno-adenosine, and N6-etheno-adenine had little affinity for recombinant A1, A2A, or A2B receptors, for a subset of P2X receptors (3H-α,β-methylene-ATP binding to rat bladder membranes), or for a subset of P2Y receptors (35S-ATP-αS binding to rat brain membranes), suggesting minimal pharmacological activity. N6-etheno-adenosine was partially converted to N6-etheno-adenine in four different cell types; this was blocked by purine nucleoside phosphorylase (PNPase) inhibition. Intravenous N6-etheno-ATP was quickly metabolized, with N6-etheno-adenine being the main product in naïve rats, but not in rats pretreated with a PNPase inhibitor. PNPase inhibition reduced the urinary excretion of endogenous adenine and attenuated the conversion of exogenous adenosine to adenine in the renal cortex. The N6-etheno-bridge method is a valid technique to assess extracellular metabolism of adenine nucleotides by ecto-nucleotidases. Also, rats express an enzyme with PNPase-like activity that metabolizes N6-etheno-adenosine to N6-etheno-adenine.

Entities:  

Keywords:  8-Aminoguanine; Ecto-nucleotidases; N6-etheno-ATP; Purine nucleoside phosphorylase

Mesh:

Substances:

Year:  2020        PMID: 32367441      PMCID: PMC7367995          DOI: 10.1007/s11302-020-09699-x

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  88 in total

Review 1.  Extracellular nucleotide signaling along the renal epithelium.

Authors:  E M Schwiebert; B K Kishore
Journal:  Am J Physiol Renal Physiol       Date:  2001-06

Review 2.  Adenosine receptors: what we know and what we are learning.

Authors:  M L Trincavelli; S Daniele; C Martini
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  Endogenous adenosine contributes to renal sympathetic neurotransmission via postjunctional A1 receptor-mediated coincident signaling.

Authors:  Edwin K Jackson; Dongmei Cheng; Stevan P Tofovic; Zaichuan Mi
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-23

4.  A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

Authors:  Varsha Gandhi; John M Kilpatrick; William Plunkett; Mary Ayres; Leigh Harman; Min Du; Shanta Bantia; Jan Davisson; William G Wierda; Stefan Faderl; Hagop Kantarjian; Deborah Thomas
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

Review 5.  Methylxanthines, inflammation, and cancer: fundamental mechanisms.

Authors:  Akio Ohta; Michail Sitkovsky
Journal:  Handb Exp Pharmacol       Date:  2011

Review 6.  The adenosinergic system: a potential player in the pathogenesis of ANCA-associated vasculitis?

Authors:  Lovis Kling; Bernhard K Krämer; Benito A Yard; Anna-Isabelle Kälsch
Journal:  Clin Exp Rheumatol       Date:  2018-05-03       Impact factor: 4.473

Review 7.  Inhibition of AMP deaminase as therapeutic target in cardiovascular pathology.

Authors:  Magdalena A Zabielska; Tomasz Borkowski; Ewa M Slominska; Ryszard T Smolenski
Journal:  Pharmacol Rep       Date:  2015-04-29       Impact factor: 3.024

Review 8.  Blood cells: an historical account of the roles of purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2015-08-11       Impact factor: 3.765

Review 9.  Purinergic signaling in the immune system.

Authors:  Francesco Di Virgilio; Marta Vuerich
Journal:  Auton Neurosci       Date:  2015-04-30       Impact factor: 3.145

Review 10.  Extracellular purines, purinergic receptors and tumor growth.

Authors:  F Di Virgilio; E Adinolfi
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

View more
  3 in total

1.  Mechanosensitive Hydrolysis of ATP and ADP in Lamina Propria of the Murine Bladder by Membrane-Bound and Soluble Nucleotidases.

Authors:  Mafalda S L Aresta Branco; Alejandro Gutierrez Cruz; Jacob Dayton; Brian A Perrino; Violeta N Mutafova-Yambolieva
Journal:  Front Physiol       Date:  2022-06-16       Impact factor: 4.755

2.  Suppressed renoprotective purines in COVID-19 patients with acute kidney injury.

Authors:  Edwin K Jackson; Georgios D Kitsios; Michael Y Lu; Caitlin M Schaefer; Cathy J Kessinger; Bryan J McVerry; Alison Morris; Bernard J C Macatangay
Journal:  Sci Rep       Date:  2022-10-17       Impact factor: 4.996

3.  Identification of the Mouse T Cell ADP-Ribosylome Uncovers ARTC2.2 Mediated Regulation of CD73 by ADP-Ribosylation.

Authors:  Mario Leutert; Yinghui Duan; Riekje Winzer; Stephan Menzel; Eva Tolosa; Tim Magnus; Michael O Hottiger; Friedrich Koch-Nolte; Björn Rissiek
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.